Sihua Lan

Dr. Sihua Lan

gastroenterology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2024 in Gene
Verified
Journal Article
Closed access
SLSihua Lan
Sihua Lan
SLSixue Liu
Sixue Liu
KWKe Wang
Ke Wang
WCWenying Chen
Wenying Chen
DZDandan Zheng
Dandan Zheng
SZShineng Zhang
Shineng Zhang

12 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YZYanyan Zhuang
Yanyan Zhuang
SLSihua Lan
Sihua Lan
WZWa Zhong
Wa Zhong
FHFengting Huang
Fengting Huang
JPJuanfei Peng
Juanfei Peng
SZShineng Zhang
Shineng Zhang
Early metastasis and resistance to traditional therapy are responsible for the poor prognosis of pancreatic adenocarcinoma patients. Metal-dependent protein phosphatases (PPMs) have been proven to play a crucial role in the initiation and progression of various tumors. Nevertheless, the expression and function of distinct PPMs in pancreatic adenocarcinoma have not been fully elucidated. In this study, we investigated the mRNA expression level, prognostic value, and the relationship between the expression of PPMs and the tumor microenvironment in pancreatic adenocarcinoma using Oncomine, TCGA and GTEx, GEO, Kaplan–Meier plotter, STRING, GeneMANIA, and HPA databases and R packages. GO and KEGG analysis revealed that PPMs and their differential co-expression genes are attributed to cell–cell adhesion and immune cell infiltration. Among these, PPM1K was downregulated in the tissue and peripheral blood of PAAD patients, whose expression level was negatively related to poor prognosis. Further to this, PPM1K was found to play a role in the epithelial–mesenchymal transition and immune infiltration. ROC curves showed that PPM1K had a good predictive value for pancreatic adenocarcinoma. The knockdown of PPM1K markedly promoted the proliferation and migration of pancreatic cancer cells, confirming its role in tumor suppressor activity in PAAD. This study demonstrates the potential clinical utility of PPM1K in tumor immunotherapy and brings about novel insights into the prognostic value of PPM1K in pancreatic adenocarcinoma.